PURPOSE: To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM). PATIENTS AND METHODS: We have prospectively analyzed the prognostic impact of antigenic markers, assessed by multiparametric flow cytometry, in a series of 685 newly diagnosed MM patients that were uniformly treated according to the GEM 2000 protocol. RESULTS: Our results show that expression of both CD19 and CD28 as well as the absence of CD117 were associated with a significantly shorter progression free-survival (PFS) and overall survival (OS). Interestingly, the CD28 expression correlated with t(14;16) and del(17p), while CD117-negative patients were associated with t(4;14) and del(13q). Simultaneous assessment of CD28 and CD117 antigens allowed stratification of patients with MM into three risk categories: poor risk (CD28 positive CD117 negative), intermediate (either both markers negative or both positive), and good risk (CD28 negative CD117 positive), with PFS rates of 30, 37, and 45 months, respectively (P = .01), and OS rates of 45, 68, and not reached, respectively (P = .0001). CONCLUSION: To the best of our knowledge, this is the first prospective analysis in which the prognostic impact of a relatively high number of antigenic markers has been simultaneously analyzed in a large series of uniformly treated patients, showing that the expression of several antigens (particularly CD28 and CD117) on bone marrow plasma cells from patients with MM can help to identify patients at high risk of progression.
PURPOSE: To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM). PATIENTS AND METHODS: We have prospectively analyzed the prognostic impact of antigenic markers, assessed by multiparametric flow cytometry, in a series of 685 newly diagnosed MM patients that were uniformly treated according to the GEM 2000 protocol. RESULTS: Our results show that expression of both CD19 and CD28 as well as the absence of CD117 were associated with a significantly shorter progression free-survival (PFS) and overall survival (OS). Interestingly, the CD28 expression correlated with t(14;16) and del(17p), while CD117-negative patients were associated with t(4;14) and del(13q). Simultaneous assessment of CD28 and CD117 antigens allowed stratification of patients with MM into three risk categories: poor risk (CD28 positive CD117 negative), intermediate (either both markers negative or both positive), and good risk (CD28 negative CD117 positive), with PFS rates of 30, 37, and 45 months, respectively (P = .01), and OS rates of 45, 68, and not reached, respectively (P = .0001). CONCLUSION: To the best of our knowledge, this is the first prospective analysis in which the prognostic impact of a relatively high number of antigenic markers has been simultaneously analyzed in a large series of uniformly treated patients, showing that the expression of several antigens (particularly CD28 and CD117) on bone marrow plasma cells from patients with MM can help to identify patients at high risk of progression.
Authors: Martin Schmidt-Hieber; Martin Pérez-Andrés; Bruno Paiva; Juan Flores-Montero; Jose J Perez; Norma C Gutierrez; Maria-Belen Vidriales; Sergio Matarraz; Jesus F San Miguel; Alberto Orfao Journal: Haematologica Date: 2010-10-22 Impact factor: 9.941
Authors: Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de Las Heras; Maria V Mateos; Maria C López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Joan Bladé; Juan J Lahuerta; Alberto Orfao; Jesús F San Miguel Journal: Blood Date: 2008-07-31 Impact factor: 22.113
Authors: J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao Journal: Leukemia Date: 2012-05-03 Impact factor: 11.528
Authors: Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron Journal: Cytometry B Clin Cytom Date: 2015-07-06 Impact factor: 3.058
Authors: Elisabet E Manasanch; Dalia A Salem; Constance M Yuan; Nishant Tageja; Manisha Bhutani; Mary Kwok; Dickran Kazandjian; George Carter; Seth M Steinberg; Diamond Zuchlinski; Marcia Mulquin; Katherine Calvo; Irina Maric; Mark Roschewski; Neha Korde; Raul Braylan; Ola Landgren; Maryalice Stetler-Stevenson Journal: Leuk Lymphoma Date: 2014-10-30
Authors: Prashant R Tembhare; Constance M Yuan; David Venzon; Raul Braylan; Neha Korde; Elisabet Manasanch; Diamond Zuchlinsky; Katherine Calvo; Roger Kurlander; Manisha Bhutani; Nishant Tageja; Irina Maric; Marcia Mulquin; Mark Roschewski; Mary Kwok; David Liewehr; Ola Landgren; Maryalice Stetler-Stevenson Journal: Leuk Res Date: 2013-12-11 Impact factor: 3.156
Authors: Bruno Paiva; Maria-Belén Vidriales; Jose J Pérez; Gema Mateo; Maria Angeles Montalbán; Maria Victoria Mateos; Joan Bladé; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel Journal: Haematologica Date: 2009-11 Impact factor: 9.941